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Summary
We have identified a somatic mutation in Op18 in a human esophageal adenocarcinoma. The mutant form of Op18 (M-Op18)
was cloned and sequenced, revealing a substitution of a G for C at nucleotide 155, which results in a Q18→E substitution
in the protein. M-Op18 cDNA was expressed in NIH/3T3 cells, which resulted in foci formation and tumor growth in immuno-
deficient mice. Cell cycle analysis of M-Op18-expressing cells revealed a doubling in the percentage of cells in G2/M
relative to cells overexpressing wild-type Op18, a decrease in M-Op18-specific phosphorylation, and alterations in tubulin
ultrastructure in M-Op18-expressing cells. These results suggest that the somatic mutation identified in Op18 has profound
effects on cell homeostasis that may lead to tumorigenicity.
Introduction (Beretta et al., 1993; Curmi et al., 1994). Being a substrate of
several kinase families, Op18 has been proposed to act as a
relay phosphoprotein for multiple signal transduction pathwaysOncoprotein 18 (Op18) is an ubiquitous, highly conserved 19
kDa cytosolic protein that has been shown to destabilize micro- (Sobel, 1991).
The importance of Op18 phosphorylation in cell cycle pro-tubules in vitro, at least in part due to tubulin sequestration
and microtubule catastrophe-promoting activities (Belmont and gression was demonstrated by using transfectants expressing
a phosphorylation site-deficient mutant form of Op18 (in whichMitchison, 1996; Horwitz et al., 1997; Jourdain et al., 1997;
Larsson et al., 1997). Op18 is expressed in proliferating cells of the four phosphorylatable serine residues were replaced with
alanines (4A mutant). Overexpression of this mutant preventedmost cell lineages (Rowlands et al., 1995), and its level increases
significantly during the S phase of the cell cycle (Cooper et al., formation of a normal mitotic spindle and led to a G2/M arrest
and subsequent polyploidization (Gavet et al., 1998; Marklund1989; Strahler et al., 1992a). The functionality of Op18 is also
tightly controlled by phosphorylation during the cell cycle et al., 1996). The 4A nonphosphorylatable mutant simulates the
active form of Op18, suggesting that downregulation of Op18-(Strahler et al., 1992a), with its activity being downregulated by
increased phosphorylation on four serine (S16, S25, S38, and mediated microtubule-destabilizing activity is required for spin-
dle formation and mitotic progression. Although overexpressionS63) residues (Gavet et al., 1998; Horwitz et al., 1997). Higher-
order phosphorylation is a prerequisite for progression through of wild-type phosphorylatable Op18 destabilized interphase mi-
crotubules, it did allow for proper spindle formation and normalmitosis. Mono- and biphosphorylated Op18 isoforms are most
abundant in cells during the S phase, and the triphosphorylated progression through the cell cycle (Gavet et al., 1998; Marklund
et al., 1996). The involvement of Op18 in spindle formationOp18 isoform is predominant in G2/M (Beretta et al., 1993;
Larsson et al., 1995; Strahler et al., 1992b). In vitro, S25 and appears to function through an interaction with tubulin dimers
that regulate microtubule dynamics (Belmont and Mitchison,S38 are targets of MAP kinases. Cyclin-dependent kinases
phosphorylate Op18 on S25 and S38 (Beretta et al., 1993; Mark- 1996).
Given its role as an important regulator in proliferation andlund et al., 1993). S16 is the target for the Ca2/calmodulin-
dependent kinases II and IV/Gr (Marklund et al., 1994). S63 differentiation, deregulated expression of Op18 may be relevant
to cancer. An increased level of Op18 expression has beenand S16 are substrates for cAMP-dependent protein kinases
S I G N I F I C A N C E
Although microtubules have been extensively studied as targets of cancer therapeutics (e.g., Taxol, vindesine, and vincristine), only
truncation mutations of the Adenomatous polyposis coli protein have been implicated in human neoplasia. The microtubule-regulating
protein Op18 has been shown to destabilize microtubules in vitro, at least in part due to tubulin sequestration and microtubule
catastrophe-promoting activities. In this report, we have identified a somatic mutation in Op18 in a human esophageal adenocarci-
noma. Functional analyses have demonstrated that expression of the mutant Op18 in NIH/3T3 cells induces transformation in vitro
and tumor development in nude mice. We have described a novel mutation in a microtubule-regulating protein, suggesting that
regulation of microtubule dynamics may have a causal relationship to human neoplasm.
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Figure 1. Identification of a somatic mutation in
Op18 in a human esophageal adenocarcinoma
A: 2D PAGE analysis of Op18 isoforms in normal
and tumor tissues. Proteins from solubilized tissues
obtained from Patient #7 were separated by 2D
PAGE, followed by silver staining, as described
in Experimental Procedures. Only the close-up
sections framing Op18 protein isoforms from nor-
mal esophageal tissue and the patient’s tumor
are shown. Op18 isoforms were identified based
on their characteristic location in 2D patterns
and based on their reactivity with an anti-Op18
antibody. Arrows point to unphosphorylated
form of Op18 (Op18) and a major phosphory-
lated isoform (Op18a). Novel proteins are indi-
cated as M-Op18 and M-Op18a. B: Detection of
C155→G mutation in the Op18 gene. Genomic
DNA was isolated from five esophageal tumors
and the corresponding normal gastric mucosa,
and the mRNA encoding Op18 was amplified by
PCR. The PCR products were digested with ScrF1
restriction enzyme and subsequently analyzed
by gel electrophoresis, as described in Experi-
mental Procedures. Lane 1: M.W. markers. Lanes
with even numbers contain PCR products ampli-
fied from normal esophageal tissue, whereas
those with odd numbers contain PCR products
amplified from esophageal tumors. ScrF1 diges-
tion of the 489 bp PCR products amplified from
wild-type Op18 gene would generate 353, 87,
31, and 17 bp fragments. The C155→G mutation
in the Op18 gene eliminates a ScrF1 site between
the 87 bp and 31 bp fragments, resulting in a 118
bp fragment, which was only observed in the
tumor but not the normal esophageal tissue of
patient #7 (lane 11 versus 10). In lane 11, the 87
bp fragment was also detected, displaying a
similar intensity as the 118 bp fragment. This is
likely to be due to contaminating cell types in
the tumor.
reported in acute leukemia (Hanash et al., 1988; Roos et al., ent in the normal, dysplastic, or tumor tissues of the other 16
patients analyzed (data not shown). The novel protein displayed1993), lymphoma (Brattsand et al., 1993; Roos et al., 1993),
neuroblastoma (Hailat et al., 1990), and breast carcinoma (Curmi a similar molecular mass as Op18 but with a more acidic isoelec-
tric point, suggesting that it may either be a variant of Op18 oret al., 2000). In this study, we have identified a somatic Q18→E
mutation in Op18 in an esophageal adenocarcinoma. Functional an unrelated protein. Using an anti-Op18 polyclonal antibody,
we examined whether this protein was an Op18 variant by 2Danalyses of this mutation demonstrated that the mutant Op18
has transforming properties. PAGE and Western blot analysis. Interestingly, the anti-Op18
antibody recognized this novel protein (not shown), thereby
indicating a potential somatic mutation(s) in Op18.Results
PolyA RNA was isolated from the tumor and subjected to
RT-PCR to amplify the Op18 cDNA. The PCR products wereA point mutation detected in the Op18 coding region
As part of a proteomic analysis of esophageal adenocarcino- purified and used directly for DNA sequencing analysis to avoid
random mutations that might be introduced by Taq polymerase.mas, two-dimensional polyacrylamide gel electrophoresis (2D
PAGE) was undertaken for 17 tumors and their corresponding A substitution of a G for C was detected at nucleotide 155 in
the Op18 cDNA.normal and dysplastic (Barrett’s) tissue. Interestingly, one tumor
showed a total lack of the major Op18 isoform by 2D PAGE, The C155→G substitution in Op18 cDNA results in an elimina-
tion of a ScrFI restriction site, providing a basis for developingas well as the appearance of a novel neighboring protein spot.
The novel protein was absent in normal and dysplastic esopha- a PCR/restriction method to screen for this mutation in genomic
DNA. Genomic DNA was isolated from normal and tumor tissuesgeal tissue from the same patient (Figure 1A) and was not pres-
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of the 17 patients. Sequences in exon 3 and intron 4 of the
Op18 gene (Melhem et al., 1991) were selected for primer design
to amplify the 489 bp fragment. Subsequently, the PCR prod-
ucts were cut with ScrFI enzyme that generated four fragments
(353 bp, 87 bp, 31 bp, and 17 bp) from the wild-type Op18
gene (Figure 1B). An elimination of a ScrFI site caused by the
C52→G mutation in the Op18 coding region would not generate
the 87 bp and 31 bp fragments but instead would create a 118
bp fragment. We observed a 118 bp fragment in the tumor with
the novel Op18 protein (Figure 1B). An additional 87 bp DNA
fragment was also detected that displayed similar band intensity
as the 118 bp fragment.
The C155→G mutation in the Op18 cDNA results in a substitu-
tion of a glutamic acid for a glutamine at residue 18 of the protein.
Using the Wisconsin Package (Genetics Computer Group, Inc.),
the calculated pI values for the wild-type and mutated Op18
are 5.87 and 5.60, respectively. The acidic shift of pI caused
by C52→G mutation in Op18 is consistent with the observed pI
value of the novel protein on the 2D gel (Figure 1A).
Generation of infectants that expressed
the mutated Op18 (M-Op18)
To further investigate the biological significance of the Q18→E
mutation in Op18, the wild-type (S-Op18), mutant Op18
(M-Op18), and antisense (AS-Op18) cDNA were subcloned into
the pTP2000 bicistronic expression vector and transfected into
the φNX retrovirus-producing cell line. The resulting retrovirus
was used to infect the NIH/3T3 cell line and allowed to integrate
into the cell genome. Stable transfectants remained as pooled
populations of cells so as not to bias the results due to potential
insertional inactivation of genes important for cell proliferation
and differentiation. Expression of wild-type (S-Op18), antisense
(AS-Op18), and the mutant form of Op18 (M-Op18) were cou-
pled to neomycin resistance in the pTP2000 retroviral vector
and were under the control of a CMV promoter. The expression
of each infectant was found to be maximal in the presence of
400 g/ml G418 (data not shown). The level of endogenous
wild-type Op18 expressed in the M-Op18 infectants was 1.5-
fold higher than M-Op18 (data not shown), and the total amount
of Op18 expressed in M-Op18 was comparable to that found
in S-Op18. The level of wild-type Op18 in the M-Op18 infectants
was similar to that found in the vector-only NIH/3T3 cell in-
fectants (data not shown), a negative control infected only with
retrovirus produced from the pTP2000 construct. In order to
demonstrate that the expressed mutant gene was indeed a
mutated form of Op18, M-Op18 and S-Op18 cell lysates were
Figure 2. Expression of M-Op18 in NIH/3T3 cells
resolved by 2D gel electrophoresis. The resolved proteins were
A: M-Op18 and S-Op18 isoforms are expressed in NIH/3T3 infectants. Proteins
transferred onto PVDF membranes and subjected to antibody from solubilized NIH/3T3 infectants were separated by 2D PAGE, as de-
hybridization with specific rabbit anti-Op18 antibodies, followed scribed in Experimental Procedures, and subjected to Western blot analysis.
Only the close-up sections framing Op18 protein are shown. Arrows point toby chemiluminescent visualization of the bound antibody (Figure
unphosphorylated forms of Op18 (labeled Op18 and Op18, respectively), a2A). Wild-type isoforms of Op18 were visualized on blots pre-
major isoform (Op18a), which is phosphorylated on one of the four phos-pared from both cell lysates. Additionally, spots of reactivity
phorylatable serine residues, and several minor isoforms, which are
appeared on the M-Op18 blots that colocalized with the spots phosphorylated on several serine residues (Op18b, c, and d, respectively).
attributed to expression of the mutant Op18. Thus, the M-Op18 The unphosphorylated mutant form of Op18 is indicated as M-Op18, and
its major phosphorylated (on a single serine residue) isoform is indicated asNIH/3T3 cells did express a mutant form of Op18, and this
M-Op18a. Interestingly, minor isoforms of M-Op18 that were phosphorylatedmutated form of Op18 had an equivalent shift in the pI to that
on several serine residues were not observed. B: M-Op18 infectants form
seen in the tumor from patient #7. Pulse-chase experiments foci when grown in culture. M-Op18 infectants were propagated in culture
(data not shown) demonstrated that the half-life of M-Op18 for up to 1 week, as described in Experimental Procedures. The cells were
photographed on an inverted microscope. Bar equals 50 m.protein was similar to that of wild-type Op18 (approximately 8
hr in both M-Op18 and S-Op18 clones). This indicates that
Q18→E mutation in Op18 did not affect its protein stability.
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Figure 3. Histology and immunohistochemistry of
tumors formed by subcutaneous inoculation of
M-Op18 into immunodeficient mice
Tumors formed subsequent to M-Op18 inocula-
tion into immunodeficient mice were harvested,
trimmed of adipose and connective tissue, and
then fixed in 10% buffered formalin. The tumors
were embedded in paraffin, sectioned, and
stained with Hematoxylin and Eosin (A and C)
or for immunohistochemistry using a cytokeratin
antibody (AE1/AE3) cocktail (B and D). The four
images shown are from the same tumor, with A
and B showing areas of high-grade neoplasm,
and C and D showing areas of high-grade ade-
nocarcinoma.
Moreover, the mutated Op18 did not appear to affect either the
level of expression or the protein stability of wild-type Op18 in
M-OP18 transfectants.
Transforming properties of M-Op18 (Q18→E)
The stably infected cell cultures were maintained in plastic cul-
ture flasks under G418 selection. Upon reaching confluence,
the M-Op18 infectants were observed to form large numbers
of foci, consisting of up to approximately 100 cells (Figure 2B).
These foci have been observed in cells cultured (without pas-
sage) for up to 2 months. Foci formation was not observed with
S-Op18, nor with infectants expressing antisense of Op18 (AS-
Op18) and vector-only controls, indicating that the specific ex-
pression of M-Op18 in NIH/3T3 cells leads to foci formation.
We ascertained the ability of both the M-Op18 and S-Op18
cell populations to grow in an anchorage-independent fashion,
a hallmark of the tumorigenic state. 1  104 cells of each in-
fectant was plated in 0.35% Noble agar over a cushion of 0.7%
Noble agar, in quintuplicate. Cells were fed full-growth medium
(90% DMEM, 10% FCS containing antibiotics and G418 [400
g/ml]) and assayed for growth at 35 days using an inverted
microscope. We observed efficient colony formation in soft agar
only with cells expressing M-Op18. M-Op18 infectants exhibited
an average of 32.3 colonies (standard deviation 14.3 colonies)
per plate, compared to an average of 2.5 colonies (SD  1.9
colonies) for S-Op18, an average of 2.3 colonies (SD  0.6
colonies) for AS-Op18, and an average of 8.7 colonies (SD 
0.6 colonies) for vector only. We next determined the ability of Figure 4. S-Op18 and M-Op18 infectants exhibit differences in growth rates
cells expressing M-Op18 to form tumors in SCID mice. 5  106 when propagated in reduced serum levels
cells (either M-Op18 or S-Op18) were inoculated subcutane- Serum-dependent growth was compared between the M-Op18 and
S-Op18 cells. 5.0  103 cells of M-Op18 and S-Op18 were cultured in 96-wellously into immunodeficient SCID C.B-17 mice in the intrascapu-
plates at 10%, 1%, or 0% serum concentration for up to 96 hr. Cell growthlar region. Tumors greater than 5 mm in diameter (range  5–7
was determined by the MTT assay. The experiment has been repeated
mm) were observed within 21 days in 10/10 mice inoculated twice.
with M-Op18. No tumors were observed in the ten mice inocu-
lated with S-Op18 cells. The tumors were harvested under sterile
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Figure 5. Cell cycle distribution of M-Op18 and
S-Op18 infectants
M-Op18 and S-Op18 infectants were plated and
grown at subconfluent levels for 48 hr and then
treated minus and plus Paclitaxel for an addi-
tional 24 hr, as described in Experimental Proce-
dures. Treatment groups were analyzed by flow
cytometry for cell cycle distribution at 72 hr fol-
lowing plating. Cell cycle distribution of S-Op18
control (absence of Paclitaxel) and in the pres-
ence of 50 nM Paclitaxel and 500 nM Paclitaxel
is shown, as is cell cycle distribution of M-Op18
control (absence of Paclitaxel) and in the pres-
ence of 50 nM and 500 nM Paclitaxel.
conditions and cell lysates were prepared from each tumor. estingly, although the Q18→E mutation had transforming prop-
erties, M-Op18 infectants exhibited a doubling time of 34.4 hrProtein expression in the tumor nodules was analyzed by 2D
PAGE. These tumors were found to maintain expression of (1.9 hr), compared to a doubling time of 23.1 hr (2.3 hr) for
S-Op18, a doubling time of 24.3 hr (2.4 hr) for AS-Op18, andM-Op18 (data not shown). Pathologically, these infected NIH/
3T3 cells expressing M-Op18 formed malignant tumor nodules a doubling time of 21.6 hr (2.1 hr) for vector only.
Serum-dependent growth was also compared between thewith biphasic morphology (Figure 3), appearing as high-grade
neoplasms with areas of high-grade adenocarcinoma. The epi- M-Op18 and S-Op18 cells. At an initial density of 5.0  103
cells/well of a 96-well plate, M-Op18 and S-Op18 were culturedthelial nature of the adenocarcinoma was evidenced by glandu-
lar formation and confirmed by expression of cytokeratins (Fig- at 10%, 1%, and 0% serum concentration for up to 96 hr. A
ure 3), whereas the component that was cytokeratin negative slower growth rate was observed for both M-Op18 and S-Op18
likely represents an undifferentiated neoplasm. when the serum level was reduced during culture (Figure 4). At
the 10% serum level, M-Op18 exhibited a lower cell density,
which apparently was reflected by its reduced growth rate rela-Effects of M-Op18 (Q18→E) on cell growth
To determine if the Q18→E mutation in Op18 affects growth tive to S-Op18. When the serum level was reduced to 1%,
M-Op18 cells displayed a much lower density relative to S-Op18properties, cells were grown at an initial density of 5  104
cells/ml for up to 4 days, and the growth rate of M-Op18 was cells. The results indicate that expression of the mutated form
of Op18 affected serum-dependent growth. Thus, although ex-compared to S-Op18, AS-Op18, and vector-only controls. Inter-
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Figure 6. M-Op18 expression results in multipolar
spindle formation in NIH/3T3 infectants
M-Op18 infectants were plated and grown at
subconfluent levels for 48 hr and then fixed and
stained for immunofluorescence with mouse
anti--tubulin antibodies as described in Experi-
mental Procedures. Mitotic spindles were ob-
served and classified as being either normal
(e.g., two poles) or multipolar (e.g., more than
two poles). Three examples of multipolar spindles
stained with the anti--tubulin antibody (A–C)
are shown, as is an example of a normal bipolar
spindle from S-Op18 infectants (D). The experi-
ment has been repeated three times. Bar equals
10 m.
pression of M-Op18 leads to cell growth retardation of a bulk population, and which could result from either apoptosis or
segregation of chromosomes to multipolar (more than two) spin-population of cells, the mutant exerts transforming properties.
dles, during mitosis. Thus, we examined the two cell populations
for levels of apoptosis but were unable to discern any differencesEffect of M-Op18 on microtubules
As the cell doubling time of the M-Op18 infectants was reduced (data not shown). Moreover, incubation in as little as 100 nM
Paclitaxel for 24 hr resulted in a significantly increased percent-relative to sense and vector-only infectants, we determined the
effect of M-Op18 on cell cycle distribution and on microtubules. age of M-Op18 cells in G2/M (42% M-Op18 as compared with
just 9% S-Op18). Incubation in 500 nM Paclitaxel resulted in anAdditionally, as the unphosphorylated form of Op18 has been
shown to bind and stabilize microtubules in vivo, we explored almost complete arrest in G2/M for M-Op18 (95.7%), whereas
S-Op18 exhibited 53.9% of the cell population in G2/M. Both cellwhether addition of various concentrations of Paclitaxel (which
in sufficient concentration will itself cause a G2/M blockage of lines exhibited a complete G2/M arrest at the highest Paclitaxel
concentration tested (1 M). Taken together, these results sug-the cell cycle) would further perturb cell cycle progression of
M-Op18 as compared with S-Op18. Both the M-Op18 and gest that expression of the mutated form of Op18 may enhance
stability of microtubules through the cell cycle (by binding to aS-Op18 stably infected cell populations were plated at subcon-
fluent levels in 10% serum for 48 hr, then treated with increasing site on polymerized microtubules distinct from the Paclitaxel
binding site). This may, in turn, lead to the accumulation ofconcentrations of Paclitaxel for an additional 24 hr. All treatment
groups were analyzed by flow cytometry for cell cycle distribu- M-Op18 at the G2/M stage of the cell cycle. Thus, we next
sought to determine whether the Op18 mutation affected spin-tion at 72 hr following plating (Figure 5). The percentages of
M-Op18-expressing cells at each stage of the cell cycle were dle formation. Both mutant and sense overexpressers were
grown in cell chambers, fixed, and then analyzed by immuno-compared with those observed with the S-Op18 cell phenotype.
In the absence of Paclitaxel, we observed a doubling of the fluorescence for either - or -tubulin-containing mitotic spin-
dles (Figure 6). Whereas 3/493 mitotic spindles were multipolarpercentage of M-Op18 cells in G2/M as compared to S-Op18,
indicating that the retardation of doubling times observed in the (more than two spindle poles) in the S-Op18 population, 14/
656 mitotic spindles were multipolar in the M-Op18 population—M-Op18 cell population most likely resulted from a G2/M cell
cycle stage-specific blockage. Intermediate concentrations of approximately a 4-fold increase in multipolar spindles in the
M-Op18-expressing cells (p  0.046, two-sided Fisher’s exactPaclitaxel (50–100 nM), which do not cause a complete G2/M
block in the cell cycle, caused the appearance of a novel sub- test).
Our results described above suggest that the mutation inG1 peak in M-Op18, consisting of 35.9%–45.8% of the total
cell population, which was not observed in S-Op18 under similar Op18 interfered with the degree of phosphorylation of the mu-
tated protein in vivo. As the dephosphorylated form of Op18conditions. The novel peak is indicative of a cell population that
contains less genomic DNA than that which appears in the G1 has been shown to bind to microtubules and stabilize tubulin
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Figure 7. M-Op18 expression results in profound
reorganization of microtubule ultrastructure in
NIH/3T3 infectants
M-Op18 and S-Op18 infectants were plated and
grown at subconfluent levels for 48 hr and then
fixed and stained for immunofluorescence with
rabbit anti-Op18 antibodies and mouse anti-
-tubulin, as described in Experimental Proce-
dures. Identical fields are shown for both the
Op18 antibody and for the anti--tubulin anti-
body. Equivalent results were obtained when an
anti--tubulin antibody was used instead of the
anti--tubulin antibody. The experiment has
been repeated five times. Bar equals 10 m.
dimers, we sought to ascertain whether expression of the mu- associated with these structures. The immunoreactive struc-
tures appear to be composed of polymerized tubulin moleculestated form of Op18 would lead to increased stabilization of
microtubules with associated changes in microtubular ultra- (e.g., microtubules), as brief treatment of M-Op18 cells with
the microtubule depolymerizing agent nocodazole caused theirstructure as compared to that visualized with S-Op18. Both
M-Op18 and S-Op18 cells were plated on chamber slides, then complete disappearance (data not shown).
subsequently stained for either -tubulin, -tubulin, or 	-tubulin
(found in centrosomes) immunofluorescence, in the presence Phosphorylation of M-Op18 is reduced as compared
with wild-type Op18or absence of immuofluorescent staining of Op18. Overall, we
observed unusual rings and swirls of both - and -tubulin The results described above suggested that expression of the
mutated form of Op18 interfered with cell cycle dynamics. Thus,immunoreactivity near the cell periphery in the NIH/3T3 cells
expressing M-Op18 (Figure 7). No similar structures were visual- we sought to ascertain the mechanistic reason(s) for the ob-
served changes in cell growth and tumorigenic potential in cellsized in NIH/3T3 cells expressing S-Op18. Further, we did not
find any differences in the numbers of centrosomes or in their expressing M-Op18. Op18 is one of the major mitotic phosphor-
ylation substrates in a number of different cell types, beingsubcellular location between M-Op18 and S-Op18 infectants,
as visualized by 	-tubulin immunofluorescence (data not phosphorylated on up to four serine residues (namely serine
16, serine 25, serine 38, and serine 63) in response to a myriadshown). The rings and swirls of - and -tubulin immunoreactiv-
ity colocalized with immunofluorescent staining patterns ob- of extracellular signals. As the mutated form of Op18 involved
an amino acid substitution (glutamine to glutamic acid) at resi-served with anti-Op18 antibodies, suggesting that Op18 was
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that phosphorylation of serine 38 was largely unaffected by the
mutant phenotype as compared with the wild-type phenotype.
In marked contrast, however, phosphorylation of serine 25 in
M-Op18 was greatly reduced when compared with that ob-
served on wild-type. Additionally, there was no phosphorylation
of serine 16 detectable in M-Op18 (although we were able to
detect it in S-Op18). This situation might result from the pertur-
bation of the epitope by the glutamine to glutamic acid substitu-
tion occurring at serine 18 and may not necessarily reflect the
true phosphorylation state of M-Op18 serine 16.
Discussion
We have uncovered in our analysis of Op18 expression in esoph-
ageal tumors a C52→G mutation in the Op18 coding region,
which results in a Q18→E substitution. This is a report of a
novel Op18 mutation found in cancer. The Q18→E substitution
in Op18 was not detected in normal esophageal and Barrett’s
tissue from the same patient, indicating it was a somatic muta-
tion that arose in the tumor. Analysis of genomic DNA revealed
a similar band intensity of the PCR products representing the
mutated and wild-type Op18 gene in the tumor that exhibited
only mutant Op18 protein. It is plausible that associated nontu-
mor cells in the tumor sample gave rise to the band representing
the wild-type PCR product. Although we cannot exclude the
possible alteration in the rate of amplifying wild-type and the
Figure 8. Western blot analysis of phosphorylated Op18 isoforms in NIH/3T3 mutant Op18 genes, it seems unlikely this would occur for two
infectants 489 bp fragments that differ in only one nucleotide. Furthermore,
Proteins from solubilized NIH/3T3 infectants were separated by 2D PAGE, the probability of the same somatic mutation occurring at two
transferred to PVDF membranes, and hybridized against phosphoserine- alleles is very rare. Thus, the C52→G mutation likely occurred
specific antibodies, as described in Experimental Procedures. Only the
at one of the two alleles in the tumor in which it was detected.close-up sections framing Op18 protein are shown. Arrows point to a major
Even though only one allele may be mutated, the tumor thatphosphorylated isoform of Op18 (labeled Op18a), a minor form (Op18a),
which is phosphorylated on one of the four phosphorylatable serine residues, expressed mutant Op18 exclusively expressed the mutant. One
and several minor isoforms, which are phosphorylated on several serine plausible explanation is that Op18 in the tumor may be monoal-
residues (Op18b, Op18b, c ,and d, respectively). The phosphorylated (on lelically expressed, specifically from the allele containing the
a single serine residue) mutant form of Op18 is indicated as M-Op18a, with
mutated Op18. Another possibility for the lack of wild-type Op18its doubly phosphorylated isoform indicated as M-Op18b.
expression in this tumor is that the region containing the wild-
type Op18 gene in the other allele may be deleted. The Op18
gene is located on chromosome 1p36 (Ferrari et al., 1990), and
the deletion of this region is commonly observed in cancersdue 18, which ultimately resulted in a full charge (plus to minus)
including breast and colon carcinomas (Farabegoli et al., 1996;difference immediately adjacent to two key phosphorylation
Tanaka et al., 1993). Based on Southern blot analysis using thesites, we postulated that the Op18 mutation might have resulted
enzymes that cut within the Op18 gene, however, we did notin decreased levels of phosphorylation of the mutant protein as
observe a gross deletion or rearrangement in the genomic DNAcompared to the levels observed with wild-type. In order to
from this tumor, as compared to tissues from the other 16evaluate the capacity of all phenotypes of the infected cells to
patients studied (data not shown). Another possibility is thatphosphorylate cellular proteins, especially the various forms of
expression of the mutated Op18 affects the expression or pro-Op18, cells were labeled in vivo with 32P for 2 hr. The labeled
tein stability of wild-type Op18. However, this is also unlikelyproteins were resolved by 2D PAGE and imaged by exposure
based on our results from pulse-chase experiments.of the dried gels to film. Op18 isoforms previously shown to be
Our data, based on the analysis of 17 esophageal tumors,phosphorylated (Wang et al., 1993) were identified, and their
indicates total loss of wild-type Op18 and the presence of onlyexpression levels were analyzed. Overall, we found that the
the mutated form in just one tumor. In the other tumors, welevels of both the mono- and biphosphorylated forms of M-Op18
cannot exclude the occurrence of small amounts of mutatedwere substantially reduced as compared with these phosphory-
Op18. Although we have observed some Op18 that migrateslated forms of wild-type Op18, while the levels of all other cellular
to the same position on 2D gel as the mutant form, such minorphosphoproteins detected remained invariant (data not shown).
forms may represent modifications other than the specific muta-To further explore which of the phosphorylation sites on the
tion we have observed, since we do not have an antibody thatM-Op18 was adversely affected by the mutated phenotype,
is specific for the mutant form.Western blot analysis of both the M-Op18 and S-Op18 was
The Q18→E mutation introduces a negative charge to Op18performed (Figure 8) using site-specific rabbit antibodies to
protein, thereby inducing a structural change that may alterphosphoserine 16, phosphoserine 25, and phosphoserine 38
(an antibody to phosphoserine 63 was unavailable). We found its proper interaction with other cellular proteins, most notably
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tubulin and various serine/threonine protein kinases (Belmont to cause the G2/M blockage that we have observed. However,
while entry into mitosis is controlled by p34-cdc2, centrosomeand Mitchison, 1996; Beretta et al., 1993; Curmi et al., 1994;
Luo et al., 1994; Marklund et al., 1993, 1994; Maucuer et al., duplication in vivo has been shown to be dependent upon p33-
cdk2 activity (Lacey et al., 1999). It is possible that the kinetics1995). By altering the interaction with kinases, phosphorylation
of the mutated Op18 may be negatively affected, especially on of association between M-Op18 and p33-cdk2 may also be
diminished sufficiently during critical portions of the cell cycle.the phosphorylatable serine residues (S16 and S25) immediately
surrounding the site of the mutation. It has been shown that Thus, with the active form of p33-cdk2 not being “sequestered”
by Op18, this may favor interactions between p33-cdk2 andwild-type Op18 exhibits a microtubule-destabilizing activity in
vivo (Belmont and Mitchison, 1996), which can be downregu- other proteins with which it could interact, which in turn could
lead to increased numbers of centrosomes, multipolar spindlelated by phosphorylation on four serine (S16, S25, S38, and
S63) residues (Gavet et al., 1998; Horwitz et al., 1997). Increased formation, aneuploidy, and subsequently tumorigenesis.
Recently, Op18 has been shown to accumulate at centro-S16 phosphorylation, in particular, suppressed the microtubule-
destabilizing activity of Op18 (Gavet et al., 1998; Melander Gra- somes in both HeLa cells and in spindles assembled from Xeno-
pus egg extracts (Kuntziger et al., 2001). The polar accumulationdin et al., 1997). We have demonstrated that overexpression of
the Q18→E mutant exhibits reduced overall phosphorylation observed in Xenopus egg extracts supplemented with mutant
forms, representing either nonphosphorylatable or hyperphos-levels. Although we have not conclusively demonstrated that
phosphorylation of S16 is negatively impacted by the Q18→E phorylatable Op18, suggests that centrosomal accumulation
of Op18 is independent of phosphorylation state. It has beenmutation, we have been unable to detect it with the anti-phos-
phoserine antibody (even though we can detect phosphorylation demonstrated, however, that many other proteins, such as tu-
bulin, nucleophosmin, pericentrin, katanin, and others, are pres-on S16 in the wild-type Op18). Decreased phosphorylation on
S16 may also significantly impact upon other known biological ent and/or do accumulate at centrosomes. It is interesting to
speculate that Op18 interacts with so-called regulatory proteinsactivities, including impairment of normal spindle formation at
mitosis and a blockage of the cell cycle (as demonstrated by in centrosomes, thereby helping to maintain mitotic apparatus
fidelity. It is possible that the Q18→E mutant failed to properlyoverexpression of a nonphosphorylatable (4A) Op18 mutant
(Gavet et al., 1998; Larsson et al., 1997; Marklund et al., 1996). interact with one of these proteins, leading to an increase in
the number of centrosomes and resulting in multipolar spindleWe have shown that overexpression of the Q18→E mutant in
NIH/3T3 cells results in a 4-fold increase in multipolar spindles formation. We did not observe changes in the numbers of cen-
trosomes or, for that matter, aneuploidy in the NIH/3T3 cellsand a doubling in the percentage of cells at G2/M by cell cycle
analysis as compared to overexpression of the wild-type form overexpressing M-Op18 as compared to those expressing
S-Op18. However, the M-Op18 cells do express a normalof Op18.
In higher eukaryotes, progression through the cell cycle is amount of wild-type Op18, possibly sufficient to maintain fidelity
in centrosome numbers in the infected NIH/3T3 cells.regulated by cyclin-dependent kinases, with entry into mitosis
being controlled by p34-cdc2 (Coleman and Dunphy, 1994). Coordination of microtubule dynamics, membrane organi-
zation, and DNA synthesis is achieved by a regulatory systemTwo of the four Op18 phosphorylatable serines, S25 and S38,
are cyclin-dependent kinase consensus phosphorylation sites. responsive to checkpoints at major transitions in the eukaryotic
cell cycle. Alterations in the levels and/or functionality of individ-Op18 is efficiently phosphorylated in vitro by the activity of p34-
cdc2 and p33-cdk2 on both of these sites (Beretta et al., 1993; ual protein participants may have profound ramifications for
downstream pathways, protein-protein interactions, and cellularBrattsand et al., 1994; Marklund et al., 1993). Additionally, ex-
pression of an Op18 S25A, S38A dominant-negative mutant homeostasis and might eventually lead to neoplastic changes
in the affected cells and tissues. The downstream events leadinghas been shown to greatly diminish the level of phosphorylation
found at S16 and that this expression was sufficient to cause to tumorigenesis in the M-Op18-expressing cells are presently
a G2/M blockage, presumably due to decreased Op18 phos- unclear. We have undertaken an extensive proteomic analysis
phorylation by cyclin-dependent kinases (Larsson et al., 1995). of the NIH/3T3 cells overexpressing M-Op18 as compared with
We have found that, although phosphorylation of S38 was the wild-type Op18, searching for differences in the expressed
largely unaffected by the mutant phenotype, phosphorylation protein profiles between these two populations of cells. We have
of S25 in M-Op18 was greatly reduced when compared with found several differences, including but not limited to vimentin
that observed on wild-type Op18, and we were unable to detect overexpression in the M-Op18 population. While the identity of
S16 phosphorylation in the M-Op18-expressing cells. It is con- most of the affected proteins remains to be determined, it is
ceivable that the Q18→E mutant phenotype we have uncovered evident that the Op18 mutation we have uncovered has a pro-
is sufficient to reduce the ability of p34-cdc2 to phosphorylate found effect on cell homeostasis and points to a potential role
Op18 S25, a phosphorylation site located just seven amino acid for Op18 in abnormal cell proliferation. Additional studies will
residues downstream of the mutation. In turn, this may (directly need to be undertaken to search for Op18 mutations in a variety
or indirectly) have had adverse effects on the phosphorylation of cancers and to develop mouse models with various Op18
of S16, located just two amino acid residues upstream of the mutations.
mutation. This decrease in phosphorylation may ultimately con-
Experimental procedurestribute to the observed doubling in M-Op18 cells at G2/M as
compared to wild-type overexpressers. An alternative possibility
Materialsis that the association kinetics between the mutant Op18 and
All cell culture reagents, including Dulbecco’s modified Eagle’s medium
either p34-cdc2 or p33-cdk2 is perturbed compared to that (DMEM, containing L-glutamine, sodium pyruvate, and pyridoxine hydro-
observed with wild-type Op18. Such a change in association chloride), Dulbecco’s phosphate buffered saline (D-PBS), fetal calf serum,
penicillin/streptomycin, and Geneticin (G-418) were obtained from GIBCO-constants between M-Op18 and p34-cdc2 might be sufficient
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BRL (Grand Island, NY). The hygromycin was purchased from Roche (India- exposed to XAR-5 X-ray film. Patterns visualized were directly compared to
both the Coomassie blue-stained sister gels, as well as to sister gel silver-napolis, IN). The 2-well chamber slides were from Nalge-Nunc (Napierville,
IL). The mouse monoclonal anti--tubulin, anti--tubulin, and anti-	-tubulin stain patterns.
antibodies were purchased from Sigma Chemical Co. (St. Louis, MO). The
rabbit anti-Op18 antibodies and the specific anti-Op18 phosphoserine anti- RT-PCR and DNA sequencing
bodies were a kind gift of Dr. Andre Sobel (INSERM, Paris, France). The PolyA mRNA was isolated from the esophageal tumor of patient #7 using
pTP2000 bicistronic expression vector and the φNX retroviral-producing a mRNA isolation kit (Invitrogen Corp., Carlsbad, CA). The purified RNA was
cell line were a kind gift of Dr. Eric Radany (University of Michigan, Ann reverse-transcribed using AMV reverse transcriptase (New England BioLabs,
Arbor, Michigan). The horseradish peroxidase-conjugated donkey anti-rabbit Beverly, MA) prior to PCR. The Op18s (CCT GTC GCT TGT CTT CTA TTC
IgG and the ECL (Enhanced Chemiluminescence) kit were obtained from ACC) and Op18a (GGG ATG GGG AGA AAG TCA GTT C) primers were
designed to amplify the Op18 cDNA containing the coding region spanningAmersham (Arlington Heights, IL). The Alexa 594 highly crossadsorbed goat
from nucleotide residue 80 to 585 (Zhu et al., 1989). Amplification wasanti-rabbit IgG, the Alexa 488 highly crossadsorbed goat anti-mouse IgG,
performed with 35 cycles consisting of denaturation at 94
C for 1 min,the DAPI (4,6-diamidino-2-phenylindole dihydrochloride), and the Paclitaxel
annealing at 68
C for 1 min, and extension at 72
C for 1 min. The PCR(Taxol) were all obtained from Molecular Probes (Eugene, OR). The anti-
products were resolved by gel electrophoresis, directly purified from theCytokeratin AE1/AE3 antibody was obtained from Roche (Indianapolis, IN).
agarose gel, and then subjected to fluorescence DNA sequencing with theThe Immobilon-P PVDF (polyvinylidine fluoride) membranes were purchased
ABI 373A Sequencer at the Core Facility of the University of Michigan.from Millipore Corp (Bedford, MA). The acrylamide used in the first-dimension
electrophoresis, urea, ammonium persulfate, and PDA (piperazine diacrylam-
Screening the C155→G mutation in the Op18 geneide) were all purchased from Bio-Rad (Rockville Centre, NY). The acrylamide
Genomic DNA was purified from the esophageal tumors and normal tissuesused in the second-dimension electrophoresis was purchased from Serva
of seven patients using the method described previously (Thoraval et al.,(Crescent Chemical, Hauppauge, NY), and the carrier ampholytes (both
1996). The Op18-3761 (GGT GAA AGA ACT GGA GAA GCG TG) and Op18-pH 4–8 and pH 3.5–10) and NP-40 were both purchased from Gallard/
4249 primers (TGG TTT AAG ATA GAC CAG GGC TTG) were selected toSchlessinger (Carle Place, NY). All other reagents and chemicals were ob-
amplify a 489 bp fragment containing the site of mutation in the Op18 gene.tained from either Fisher or Sigma and were of the highest purity available.
PCR was performed with 35 cycles consisting of denaturation for 1 min at
94
C, annealing for 1 min at 60
C, and extension for 1 min at 72
C. TheCell growth
amplified products were digested with ScrF1 restriction enzyme and subse-Both the φNX retroviral-producing cell line and the NIH/3T3 cells were
quently analyzed by gel electrophoresis. The DNA fragments in the gel werecultured at 37
C in a 6% CO2-humidified incubator in DMEM supplemented
stained with ethidium bromide for visualization.with 10% fetal calf serum, 100 U/ml penicillin, and 100 U/ml streptomycin.
The cells were passaged weekly upon reaching confluence. Once infected
Generation of NIH/3T3 infectants that expressedwith the retrovirus, each population of NIH/3T3 cells was maintained as
the mutated Op18 (M-Op18)above, with the additional presence of either 100 g/ml hygromycin or 400
The mutant Op18 cDNA obtained by RT-PCR from the esophageal tumorg/ml Geneticin.
of patient #7 was cloned into the pCRII vector (Invitrogen). The resultant
pCRII-Op18mt plasmid was subjected to a second round of DNA sequencingQuantitative 2D PAGE and Western blotting
prior to further studies. Additionally, a 555 bp wild-type Op18 cDNA wasPatients undergoing resection for esophageal cancer by the General Tho-
also subcloned into the pCRII vector. Both cDNAs were subsequently clonedracic Surgery Section at The University of Michigan Hospital between 1991
into the pTP2000 bicistronic expression vector. The resulting constructsand 1994 were evaluated for inclusion in this study. All patient identifiers
were used to transfect the φNX retroviral-producing cell line. Briefly, φNXwere removed. Consent was received from all patients, and the protocol
cells were grown to approximately 70% confluence. Fifty micrograms ofapproved by The University of Michigan Institutional Review Board (Medi-
each pTP2000 construct (vector only, sense wild-type, antisense wild-type,cine). Fresh tumor tissue and nontumor containing normal esophagus and
and mutant) was introduced into the φNX cells by calcium phosphate trans-gastric mucosa was obtained from patients with esophageal or gastric cardia
fection. The resultant supernatants were harvested 48 hr after transfectiontumors. Following excision, the tumor tissue was immediately frozen at
and subjected to centrifugation at 1000  g for 15 min at 4
C, followed by–80
C. Only tumors with greater than 70% cellularity were used in this study.
centrifugation at 3600  g for 15 min at 4
C, then frozen at 80
C until use.Total proteins in tissues and the infected NIH/3T3 cells (described below)
The NIH/3T3 cells were plated at 40%–50% confluence and then exposedwere analyzed by 2D PAGE (Strahler et al., 1989). Briefly, proteins were
to the retrovirus-containing supernatants for 4 hr in the presence of 4 g/mlsolubilized with lysis buffer, containing 8 M urea, 2% pH 3.5–10 carrier
hexadimethrine bromide (Sigma). Following a brief wash, the cells wereampholytes, 2% -mercaptoethanol, 2% Nonidet-P40, and 10 mM PMSF.
incubated for 48 hr in DMEM containing 10% fetal calf serum and antibiotics.Isoelectric focusing was carried out for 13,200 volt-hours at room tempera-
Infectants were selected with hygromycin at an optimal concentration ofture, using pH 4–8 carrier ampholytes. The first-dimension tube gel was
300 g/ml. The Op18 protein isoforms of each infectant were evaluated byloaded onto a cassette containing the second-dimension gel, after equilibra-
2D PAGE.tion in second-dimension sample buffer (125 mM Tris [pH 6.8], containing
10% glycerol, 2% SDS, 1% dithiothreitol, and bromophenol blue). Separa-
Soft agar transformationtion in the second dimension was performed by electrophoresis in 11%–14%
To analyze the ability of the Op18 transfectants to exhibit anchorage indepen-polyacrylamide gradient SDS gels, and the samples were electrophoresed
dent growth, cells were assayed for their ability to form colonies in soft agar.until the dye front reached the opposite end of the gel. Gels were silver-
1  104 cells of each infectant were plated in 0.35% Noble agar over astained and digitized for protein spot quantitation as previously described
cushion of 0.7% Noble agar, in quintuplicate. Cells were fed full-growth(Kuick et al., 1987). Radioactivity of phosphoprotein patterns were visualized
medium (90% DMEM, 10% FCS containing antibiotics and G418 [400g/ml])and quantitated by phosphorimage technology (Johnston et al., 1990). For
and assayed for colony formation at 35 days using an inverted microscope.some gels, the resolved proteins were transferred to an Immobilon-P PVDF
membrane. Protein patterns on some membranes were visualized by Coo-
massie blue staining of the membranes. Unstained membranes prepared Cell cycle analysis
Cell cycle analysis was performed at The University of Michigan Cancerfor hybridization were incubated with blocking buffer (consisting of Tris
buffered saline [TBS] containing 1.8% nonfat dry milk and 0.1% Tween 20) Center Flow Cytometry Core Facility according to standard procedure.
Briefly, the NIH/3T3 infectants were plated and grown at subconfluent levelsfor 2 hr, then washed and incubated with specific primary antibodies diluted
in blocking buffer for 1 hr at room temperature. Following three washes for 48 hr in 100 cm2 tissue culture dishes and then treated with increasing
concentrations of Paclitaxel for an additional 24 hr. All treatment groupswith blocking buffer, the membranes were incubated with a horseradish
peroxidase-conjugated donkey anti-rabbit IgG antibody (at a 1:1000 dilution) were analyzed by flow cytometry for cell cycle distribution at 72 hr following
plating. Cells were resuspended by brief trypsinization and washed in D-PBS.for 1 hr at room temperature. The membranes were washed five times with
TBS containing 0.1% Tween 20, once in TBS, briefly incubated in ECL, and 1  106 cells per sample were resuspended in 0.5 ml D-PBS, then fixed by
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Cell cycle regulated phosphorylation of oncoprotein 18 on Ser16, Ser25,addition of 0.5 ml cold 100% ethanol (added dropwise while vortexing).
and Ser38. Eur. J. Biochem. 20, 359–368.Cells were incubated on ice for 20 min, then pelleted by centrifugation at
1000  g for 5 min. The tubes were inverted in order to remove ethanol. Coleman, T.R., and Dunphy, W.G. (1994). Cdc2 regulatory factors. Curr.
Following addition of 0.5 ml of propidium iodide-RNase solution (50 g/ml Opin. Cell Biol. 6, 877–882.
propidium iodide, 100 g/ml RNase [Type 1-A] in D-PBS) and 50 l of trout
Cooper, H.L., McDuffie, E., and Braverman, R. (1989). Human peripheralred cell nuclei (an internal control for peak positioning and ploidy; Riese
lymphocyte growth regulation and response to phorbol esters is linked toEnterprises, Grass Valley, CA), the samples were mixed and incubated in
synthesis and phosphorylation of the cytosolic protein, prosolin. J. Immunol.the dark for 20 min. 1 104 cells per sample were analyzed by Flow Cytome-
143, 956–963.try using the Coulter Elite Software Package (Beckman-Coulter, Miami, FL)
for analysis of DNA content (propidium iodide labeling of nuclei). The Multicy- Curmi, P.A., Maucuer, A., Asselin, S., Lecourtois, M., Chaffotte, A., Schmitter,
cle Software Package (Phoenix Flow Systems, San Diego, CA) was used to J.M., and Sobel, A. (1994). Molecular characterization of human stathmin
determine the percentage of cells in each stage of the cell cycle. expressed in Escherichia coli: site-directed mutagenesis of two phosphoryla-
table serines (Ser-25 and Ser-63). Biochem. J. 300, 331–338.
Immunofluorescence
Curmi, P.A., Nogues, C., Lachkar, S., Carelle, N., Gonthier, M.P., Sobel, A.,
The NIH/3T3 infectants were grown in 2-well chamber slides for 48 hr, then Lidereau, R., and Bieche, I. (2000). Overexpression of stathmin in breast
fixed in 2% formaldehyde, freshly prepared from paraformaldehyde. The carcinomas points out to highly proliferative tumours. Br. J. Cancer 82,
fixed cells were washed briefly in D-PBS (Dulbecco’s Phosphate Buffered 42–50.
Saline) and permeabilized by addition of 0.2% Tween 20 (in D-PBS). Alde-
Farabegoli, F., Ceccarelli, C., Santini, D., Trere, D., Baldini, N., Taffurelli,hyde groups resulting from fixation were quenched in 50 mM glycine (in
M., and Derenzini, M. (1996). Chromosome 1 aneusomy with 1p36 under-D-PBS), after which the fixed monolayers were washed three times in D-PBS
representation is related to histologic grade, DNA aneuploidy, high c-erb(containing 1 mg/ml BSA). Each chamber was incubated with 0.5 ml of the
B-2 and loss of bcl-2 expression in ductal breast carcinoma. Int. J. Cancerappropriate primary antibody diluted as indicated in D-PBS (containing 1
69, 381–385.
mg/ml BSA) for 45 min at room temperature. The monolayers were washed
in D-PBS (containing 1 mg/ml BSA), then incubated with 0.5 ml D-PBS Ferrari, A.C., Seuanez, H.M., Hanash, S.M., and Atweh, G.F. (1990). A gene
that encodes for a leukemia-associated phosphoprotein (p18) maps to chro-(containing 1 mg/ml BSA) containing either 20 g/ml highly crossadsorbed
mosome band 1p35-36.1. Genes Chromosomes Cancer 2, 125–129.Alexa-594-conjugated goat anti-rabbit IgG (used when rabbit serum was
used as the primary antibody) or 20 g/ml highly crossadsorbed Alexa-488- Gavet, O., Ozon, S., Manceau, V., Lawler, S., Curmi, P., and Sobel, A. (1998).
conjugated goat anti-mouse IgG (used when a mouse monoclonal antibody The stathmin phosphoprotein family: intracellular localization and effects on
was used as the primary antibody). The stained monolayers were washed the microtubule network. J. Cell Sci. 111, 3333–3346.
three times in D-PBS (containing 1 mg/ml BSA) and three times in D-PBS,
Hailat, N., Strahler, J., Melhem, R., Zhu, X.X., Brodeur, G., Seeger, R.C.,after which a glass coverslip was mounted on the monolayers in GEL/
Reynolds, C.P., and Hanash, S.M. (1990). N-myc gene amplification in neuro-MOUNT (Biomeda Corp., Foster City, CA). Fluorescent images were visual-
blastoma is associated with altered phosphorylation of a proliferation relatedized through a Leitz Orthoplan Microscope and processed through a Sony
polypeptide (Op18). Oncogene 5, 1615–1618.Digital Imaging Camera.
Hanash, S.M., Strahler, J.R., Kuick, R., Chu, E.H.Y., and Nichols, D. (1988).
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